Arif S, Vallian S, Farzaneh F, Zanone M M, James S L, Pietropaolo M, Hettiarachchi S, Vergani D, Conway G S, Peakman M
Department of Immunology, King's College School of Medicine, London, United Kingdom.
J Clin Endocrinol Metab. 1996 Dec;81(12):4439-45. doi: 10.1210/jcem.81.12.8954056.
Autoantibodies directed against steroid hormone-producing cells (SCA) detectable by immunofluorescence are typically found in a small proportion of patients with premature ovarian failure (POF) as well as in other endocrine autoimmune diseases. The SCA pattern stains cells in the outer zones of the adrenal cortex, ovary, and testis. To identify the molecular target of SCA, an adrenal complementary DNA expression library was screened using SCA-positive serum, and the steroid enzyme 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) was identified. Only 1 of 48 (2%) patients with idiopathic POF, not pre-selected for the presence of other autoimmune diseases, had SCA by immunofluorescence, whereas 10 of 48 (21%) had anti-3 beta HSD autoantibodies detectable by immunoblot using recombinant human enzyme compared with 6 of 115 (5%) control subjects (P = 0.002). Absorption of SCA-positive serum with recombinant human 3 beta HSD abolished the immunofluorescence pattern. We also examined the prevalence of anti-3 beta HSD autoantibodies in other endocrine autoimmune diseases. Two of 112 (2%) diabetic patients, but none of the thyroid or Addisonian patients, had SCA by immunofluorescence. Twenty-six (23%) diabetic subjects (P < 0.001 vs. controls), 3 of 18 thyroid patients (P > 0.05 vs. controls), and none of 4 Addisonian patients had anti-3 beta HSD autoantibodies. 3 beta HSD is the first steroid cell autoantigen defined at the molecular level to be associated with idiopathic POF occurring in the absence of other polyglandular diseases. Autoantibodies to 3 beta HSD in patients with other organ-specific autoimmune diseases indicate that the enzyme behaves as a typical target of polyendocrine autoimmunity. Anti-3 beta HSD autoantibodies in patients with POF may provide a marker of those subjects whose ovarian failure is autoimmune in origin and, as recent studies suggest, may be salvageable with glucocorticoid treatment.
通过免疫荧光法可检测到的针对类固醇激素生成细胞(SCA)的自身抗体,通常在一小部分卵巢早衰(POF)患者以及其他内分泌自身免疫性疾病患者中出现。SCA模式可使肾上腺皮质、卵巢和睾丸外层区域的细胞染色。为了确定SCA的分子靶点,利用SCA阳性血清筛选肾上腺互补DNA表达文库,鉴定出类固醇酶3β-羟基类固醇脱氢酶(3βHSD)。在48例未因存在其他自身免疫性疾病而预先选择的特发性POF患者中,只有1例(2%)通过免疫荧光法检测到SCA,而48例中有10例(21%)通过使用重组人酶的免疫印迹法检测到抗3βHSD自身抗体,相比之下,115例对照受试者中有6例(5%)检测到该抗体(P = 0.002)。用重组人3βHSD吸收SCA阳性血清可消除免疫荧光模式。我们还检测了其他内分泌自身免疫性疾病中抗3βHSD自身抗体的患病率。112例糖尿病患者中有2例(2%)通过免疫荧光法检测到SCA,但甲状腺疾病患者或艾迪生病患者中均未检测到。26例(23%)糖尿病受试者(与对照组相比,P < 0.001)、18例甲状腺疾病患者中有3例(与对照组相比,P > 0.05)以及4例艾迪生病患者中均未检测到抗3βHSD自身抗体。3βHSD是在分子水平上确定的首个与无其他多腺体疾病情况下发生的特发性POF相关的类固醇细胞自身抗原。其他器官特异性自身免疫性疾病患者中针对3βHSD的自身抗体表明,该酶表现为多内分泌自身免疫的典型靶点。POF患者中的抗3βHSD自身抗体可能为那些卵巢功能衰竭源于自身免疫的受试者提供一个标志物,并且正如最近的研究所表明的,这些患者可能可通过糖皮质激素治疗挽救。